If Natco (Activis) prevails in the patent litigation against CELG, the stock will crater. Revlimid is $5 billion in sales for CELG or 65%. Even if they win at the lower level, Activis will appeal. Companies with patent suits on their major drug are dangerous places to be. CELG other drug are years away from approval.
Natco has no case - markman will show that - the briefs already do....CELG stock is trading like they lost all 19 patents - which is impossible - Supreme court now says yesterday in frivolous generic cases like this generic companies will be responsible for all legal fees...they will pay.
CELG will be back to all time highs this yr and $200s in 2015 - this Indian blackmail company Natco is about to get its head handed to them in NJ court.